Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified lineup of products than ...

Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...

Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Drugmakers Eli Lilly and Novo Nordisk have been sued in Texas by a compounding pharmacy that alleges they are illegally ...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

Humana’s CenterWell pharmacy will dispense GLP-1 weight loss drugs made by Eli Lilly as part of a new program for employers ...

At the J.P. Morgan Healthcare Conference, Nvidia announced major AI partnerships with Lilly and Thermo Fisher Scientific to ...

Eli Lilly's research and development head said on Monday the company will have plenty of supply to launch its ...

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...